Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s mRNA engineering technology platform VERSagile and lead therapeutic candidate VMB-100 at the BIO Asia-Taiwan Conference, taking place on 27-31 July 2022 in Taiwan. Read more…
Focused on delivering highly effective vaccines against life-threatening respiratory viral infections Exclusive commercial licence to technology platform developed at The University of Queensland Industry leader Dr Emmanuel Hanon appointed Chief Executive Officer London, UK, 21 July 2022: Vicebio Ltd (“Vicebio”), a biopharmaceutical company founded by medicxi in 2019, today announces its launch to accelerate the […]
Highly experienced US medtech leader brings more than 40 years’ experience Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent Non-Executive Director of the Company. Mr. […]
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in validated clinical measures Heart failure disease-modifying profile – […]
FDA clarifies Phase 3 and US registration pathway for XF-73 Nasal gel for the prevention of post-surgical staphylococcal infections Feedback enables the Phase 3 study design to be simplified and is expected to shorten the overall clinical development timelines Brighton, United Kingdom – 19th July 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company […]
